mrc-5

LTX315 acetate (Oncopore acetate) is an oncolytic peptide with potent anticancer activity, with IC50 values of 34.3 µM for MRC-5, 8.3 µM for A20, and 11 µM for AT84, respectively.

BRC4wt, an acetylated peptide originating from the BRC4 repeat within human BRCA2 (1521-1536), acts as an inhibitor of the BRCA2 and RAD51 protein-protein interaction. When linked to the cationic cell-penetrating peptide (Arg)9, it effectively shortens DNA replication tract lengths and diminishes the frequency of homologous repair of camptothecin-induced DNA damage in vitro. Additionally, BRC4wt enhances the efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib in inducing cell death in HeLa human cervical cancer and U2OS human osteosarcoma cells, albeit it does not affect non-cancerous hTERT RPE-1, MRC-5, or MCF-10A cells.

LTX-315 (Oncopore), the oncolytic peptide, inhibits cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization.